| abstract |
Substituted indoloquinoxalines of the general formula I n<CHEM>n in R1 represents one or several, preferably 1 to 4, similar or different substituents in the positions 1-4 and/or 7-10, selected from halogen, preferably Br, lower alkyl/alkoxy group having not more than 4 carbon atoms, trifluoromethyl group, trichloromethyl group;n X is a group -(CH2)n-R2 wherein R2 represents a nitrogen containing basic residue such as NH2, NHR4 or NR5R6 wherein R4, R5 and R6 independently are lower alkyl or cykloalkyl and n is an integer of from 1 to 4 andn R3 represents hydrogen, lower alkyl/cykloalkyl group having not more than 4 carbon atoms,n and the physiologically acceptable addition products of the compounds with acids and halogen adducts, preferably adducts with iodine, iodine monochloride or iodine monobromide. n<??>Also methods for preparing said compounds by reacting a compound of the formula II n<CHEM>n with a reactive compound containing the residue -CHR3X, or by rearranging a compound the formula III n<CHEM>n by heating are described. n<??>The novel indoloquinoxalines have antiviral effect and have effect against cancer. |